A pairing appears on this page only when a trial gave both ingredients together and measured the result. Phosphorylethanolamine has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Phosphoethanolamine and phosphocholine are the parallel intermediates of the two branches of the Kennedy pathway, feeding phosphatidylethanolamine and phosphatidylcholine respectively. They draw on the same CTP pool and the same diacylglycerol pool at the final condensation step. Supplying both branches at once is what a mixed phospholipid preparation does by default. This is membrane building block arithmetic, not evidence that either intake changes a health outcome.
The liver converts phosphatidylethanolamine to phosphatidylcholine through three sequential methylations by PEMT, and each one consumes an S-adenosylmethionine molecule. Without adequate methyl donor supply that route stalls and the cell leans harder on the choline branch. So the fate of anything entering the ethanolamine branch depends on methylation status.
Betaine donates a methyl group to homocysteine to regenerate methionine, which is what refills the SAM-e pool that PEMT draws on. The three methylations that turn phosphatidylethanolamine into phosphatidylcholine are among the largest consumers of SAM-e in the liver. Betaine intake and the ethanolamine branch of phospholipid synthesis are therefore linked through the same methyl budget.
5-methyltetrahydrofolate supplies the other route back to methionine, working through methionine synthase alongside the betaine route. Both routes ultimately determine how much SAM-e is available for phospholipid methylation. This is a supply relationship in shared metabolism and says nothing about a clinical effect of taking phosphoethanolamine itself.
Methionine synthase needs methylcobalamin to move the folate methyl group onto homocysteine. When B12 is low that transfer fails and folate becomes trapped in its methyl form, which constrains the same SAM-e pool the phospholipid methylation route depends on. The dependency is a chain, so the weakest link in it sets the ceiling.
Sphingosine-1-phosphate lyase is a pyridoxal-5-phosphate dependent enzyme, and the reaction it catalyses releases phosphoethanolamine along with a fatty aldehyde. That is one of the endogenous routes by which phosphoethanolamine is generated, tying sphingolipid turnover to the ethanolamine pool. Low B6 status slows that step.
Ethanolamine kinase phosphorylates ethanolamine using ATP, and like essentially all kinases it acts on the magnesium-ATP complex rather than on free ATP. Magnesium is therefore an obligate participant in the first committed step of the ethanolamine branch. This applies to every ATP-dependent step in the pathway, not just this one.
Mammalian cells make phosphatidylserine by swapping the head group of phosphatidylethanolamine for serine, and they can run the exchange in the other direction by decarboxylating phosphatidylserine back to phosphatidylethanolamine in the mitochondria. The two lipids are interconvertible rather than independent. Anything shifting the ethanolamine pool therefore touches the serine pool as well.
Serine is the head group donor in the base exchange reaction that converts phosphatidylethanolamine to phosphatidylserine. Serine availability is one determinant of how the two head group pools distribute. This is bench biochemistry and has not been shown to be rate limiting at ordinary dietary serine intakes.
Phosphatidylcholine and phosphatidylethanolamine are the two dominant phospholipids in mammalian membranes, and their ratio governs membrane curvature and the behaviour of proteins embedded in the bilayer. Supplying one head group family without the other shifts that ratio in cell models. Mixed phospholipid preparations supply both, which is why they are formulated that way.
Commercial lecithin is a phospholipid mixture in which phosphatidylethanolamine typically sits second by weight behind phosphatidylcholine. Anyone taking lecithin is already taking the ethanolamine-headed phospholipid, delivered as an intact lipid rather than as the free phosphomonoester. The two are not interchangeable in the gut, since the intact lipid is digested by phospholipases before absorption.
Ethanolamine-headed phospholipids in neural and retinal tissue are unusually enriched in docosahexaenoic acid at the second position of the glycerol backbone. The head group and the fatty acid are assembled into the same molecule, so the supply of both matters to the final species produced. Measurements of membrane composition are not the same as a functional outcome, and that distinction holds here.
Phosphatidylethanolamine generated inside mitochondria by phosphatidylserine decarboxylase is a structural requirement for normal cristae shape and for the assembly of respiratory chain supercomplexes, which is the environment coenzyme Q10 works in. Whether supplemental intake of either shifts that environment in a person has not been shown. Read the pairing as mechanistic context rather than as a recommendation to combine them.
Nothing specific on file for Phosphorylethanolamine. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 2 we read for Phosphorylethanolamine. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.